Castleport Test Prep

NMTCB Practice Test: 50 Free Questions With Explanations

These 50 original, unofficial practice questions follow the five-domain weighting of the NMTCB entry-level nuclear medicine technologist (CNMT) exam. Pick an answer, then open "Show answer and explanation" to see the key, why each other choice misses, and the source behind it.

Practice questions

Question 1 of 50

V. Clinical Procedures · NMTCB-001

A patient is having a regadenoson pharmacologic stress myocardial perfusion study. Which administration sequence matches the regadenoson label?

  • A. Regadenoson as a 6-minute weight-based infusion, with the perfusion agent injected at the 3-minute mark of the infusion
  • B. Perfusion agent first, then regadenoson 0.4 mg 10 minutes later, with no saline flush between the two
  • C. Regadenoson 0.4 mg/5 mL within 10 seconds, a 5 mL saline flush right away, then the perfusion agent 10 to 20 seconds after the flush
  • D. Regadenoson 0.4 mg over 2 minutes, then the perfusion agent 5 minutes later once the heart rate has peaked
Show answer and explanation

Correct answer: C. The regadenoson label gives a fixed dose of 5 mL (0.4 mg) as a rapid intravenous injection within 10 seconds into a peripheral vein, using a 22-gauge or larger catheter or needle. A 5 mL saline flush follows immediately, and the myocardial perfusion agent is given 10 to 20 seconds after the saline flush; it may go into the same catheter. The fixed, rapid bolus is what separates regadenoson from older weight-based adenosine infusions.

Why the other choices don't fit

  • A: A 6-minute weight-based infusion describes adenosine protocols, not regadenoson, which is a fixed-dose bolus.
  • B: The tracer goes after regadenoson and the flush. Injecting it first would image the heart at rest, not under stress.
  • D: The label calls for injection within 10 seconds, not over 2 minutes, and the tracer follows within seconds, not minutes.

Source: DailyMed, Regadenoson Injection label (Hospira), section 2, Dosage and Administration (0.4 mg/5 mL within 10 seconds; 5 mL saline flush; radiopharmaceutical 10–20 seconds after flush)

Question 2 of 50

III. Pharmaceutical and Radiopharmaceutical Agents · NMTCB-002

A colorimetric aluminum breakthrough test on a fresh Tc-99m generator eluate shows 15 µg Al per mL. According to the TechneLite label, what should happen to this eluate?

  • A. Use it only for sulfur colloid, since aluminum doesn't affect colloid kits
  • B. Don't use it, because the label limit is 10 µg aluminum per mL of eluate
  • C. Dilute it with saline until the reading falls below the limit, then use it
  • D. Use it, because the label limit is 20 µg aluminum per mL of eluate
Show answer and explanation

Correct answer: B. The TechneLite label states that the eluate must contain no more than 10 micrograms of aluminum per mL, that the user must determine this before administration, and gives a colorimetric aluminum ion test procedure for doing it. A result of 15 µg/mL fails that limit, so the eluate shouldn't be used to prepare radiopharmaceuticals. The aluminum comes from the alumina column the Mo-99 is adsorbed on. Excess aluminum is a chemical purity problem, separate from radionuclidic purity (Mo-99 breakthrough) and radiochemical purity (free pertechnetate versus bound tracer).

Why the other choices don't fit

  • A: The 10 µg/mL limit applies to the eluate itself, whatever kit it ends up in. Choosing a different kit doesn't rescue an eluate that fails.
  • C: Dilution lowers the concentration per mL without changing the total aluminum, and the label doesn't allow 'fixing' a failed eluate this way.
  • D: The TechneLite limit is 10 µg/mL. A limit of 20 µg/mL would let a failing eluate through.

Source: DailyMed, TechneLite (technetium Tc 99m generator) label, Dosage and Administration, eluate testing (aluminum ion concentration not more than 10 µg/mL)

Question 3 of 50

IV. Instrument Operations and Quality Control · NMTCB-003

A department is setting up a dose calibrator linearity test using the decay method. Which setup follows the approach described in the IAEA nuclear medicine physics handbook?

  • A. Measure three different radionuclides once each and confirm that every reading matches its supplier's label
  • B. Start with the highest Tc-99m activity likely to be used clinically and measure it repeatedly over at least 5 days
  • C. Measure a Cs-137 check source once on every radionuclide setting and compare the readings with each other
  • D. Measure a low-activity Tc-99m vial over 6 hours, since linearity problems show up only at the bottom of the range
Show answer and explanation

Correct answer: B. Linearity asks whether the dose calibrator reads correctly across the whole range of activities it is used for. In the decay method described by the IAEA handbook, a vial with a high activity of Tc-99m is measured repeatedly over a period of at least 5 days, starting with the highest activity likely to be used in clinical practice, usually the first elution from a new generator. A semi-log plot of the background-corrected readings should follow the expected decay line; a deviation at high activities points to saturation of the ionization chamber. Accurate background readings at each assay matter more and more as the source decays, because background becomes a larger share of the reading.

Why the other choices don't fit

  • A: Comparing readings against supplier activity for several radionuclides is the accuracy test, not linearity.
  • C: Measuring a long-lived check source on each setting is the daily constancy check. It doesn't test response across a range of activities.
  • D: Saturation problems typically show up at high activities, and 6 hours covers only one Tc-99m half-life, far too narrow a range.

Source: IAEA, Nuclear Medicine Physics: A Handbook for Teachers and Students (2014), Chapter 9, section 9.2.1.2, Linearity, and section 9.2.1.1, Accuracy and reproducibility

Question 4 of 50

V. Clinical Procedures · NMTCB-004

Which patient history is listed as a contraindication to regadenoson on its label?

  • A. Mild asthma that is well controlled on a daily inhaled steroid
  • B. A prior Tc-99m sestamibi study done three months ago
  • C. Second-degree AV block with no functioning artificial pacemaker
  • D. A beta-blocker taken the morning of the test with water
Show answer and explanation

Correct answer: C. The regadenoson label lists two contraindications: second- or third-degree AV block, and sinus node dysfunction, unless the patient has a functioning artificial pacemaker. The label's warnings explain why: adenosine receptor agonists, including regadenoson, can depress the SA and AV nodes and may cause first-, second- or third-degree AV block or sinus bradycardia, so an existing conduction problem without pacemaker backup is a serious risk. Technologists screen for these during the pre-test history and ECG review. Bronchoconstriction in patients with COPD or asthma is addressed in the label's warnings rather than as a contraindication, so lung disease calls for caution and monitoring, not automatic cancellation.

Why the other choices don't fit

  • A: The label handles bronchoconstriction under warnings and precautions, not contraindications. Well-controlled mild asthma isn't a labeled contraindication.
  • B: A previous myocardial perfusion study has no bearing on whether regadenoson can be given.
  • D: Medication timing may affect protocol choices, but a beta-blocker isn't a labeled contraindication to regadenoson.

Source: DailyMed, Regadenoson Injection label (Hospira), section 4, Contraindications, and section 5, Warnings and Precautions

Question 5 of 50

II. Radiation Safety and Regulations · NMTCB-005

During a routine survey, a meter held 30 cm from the front of a hot-lab storage cabinet reads 7 mrem/h. The highest reading anywhere 30 cm from the cabinet is 9 mrem/h. Under NRC rules, which posting does this area need?

  • A. "GRAVE DANGER, VERY HIGH RADIATION AREA," because the readings are taken this close to the source
  • B. No posting at all, because these readings fall below the 100 mrem in 1 hour posting threshold
  • C. "CAUTION, RADIATION AREA," because a person could receive more than 5 mrem in 1 hour at 30 cm
  • D. "CAUTION, HIGH RADIATION AREA," because the reading exceeds 2 mrem/h, the public limit for an hour
Show answer and explanation

Correct answer: C. NRC defines a radiation area as an accessible area where radiation levels could give a person more than 0.005 rem (5 mrem) in 1 hour at 30 cm from the source or from any surface the radiation penetrates. A high radiation area starts above 0.1 rem (100 mrem) in 1 hour at 30 cm. Readings of 7 to 9 mrem/h at 30 cm fall between those two thresholds, so the area is a radiation area and 10 CFR 20.1902(a) requires a conspicuous sign with the radiation symbol and the words "CAUTION, RADIATION AREA." The 30 cm distance is built into the definitions, so surveys for posting decisions should be taken at that distance. Room postings for stored radioactive material ("CAUTION, RADIOACTIVE MATERIAL(S)") are a separate requirement based on quantity, not dose rate.

Why the other choices don't fit

  • A: A very high radiation area means more than 500 rads (5 grays) in 1 hour at 1 meter. These readings are nowhere near that, and 30 cm is the distance the definitions use.
  • B: 100 mrem in 1 hour is the high radiation area threshold. A radiation area posting is already required above 5 mrem in 1 hour at 30 cm.
  • D: 2 mrem in any one hour is the public limit for unrestricted areas in 10 CFR 20.1301, not the trigger for a high radiation area. That posting starts above 100 mrem in 1 hour at 30 cm.

Source: eCFR, 10 CFR 20.1003, Definitions, definitions of Radiation area, High radiation area and Very high radiation area; eCFR, 10 CFR 20.1902, Posting requirements, paragraphs (a) and (b)

Question 6 of 50

I. Radiation Physics and Detection · NMTCB-006

A Mo-99/Tc-99m generator label lists a Mo-99 half-life of 66 hours and a Tc-99m half-life of 6.02 hours. Several days after the last elution, the Tc-99m on the column is decaying at the same rate as its Mo-99 parent. What kind of parent-daughter relationship is this?

  • A. Transient equilibrium, because the daughter's half-life is shorter than the parent's but not vastly shorter
  • B. No equilibrium at all, because when the daughter half-life is shorter, the daughter activity keeps falling toward zero
  • C. Isomeric equilibrium, because Tc-99m decays by isomeric transition, which sets the rate for the parent
  • D. Secular equilibrium, because any daughter that grows in from a longer-lived parent eventually matches it
Show answer and explanation

Correct answer: A. When a daughter has a shorter half-life than its parent, the daughter grows in, and after enough time the ratio of daughter to parent activity settles at a constant value. From then on the daughter appears to decay with the parent's half-life. The IAEA handbook calls this transient equilibrium when the daughter half-life is shorter than the parent's, and reserves the name secular equilibrium for the special case where the daughter's half-life is much shorter, so the two activities become essentially identical. Tc-99m (6.02 h) is shorter-lived than Mo-99 (66 h), but only by a factor of about 11, so the Mo-99/Tc-99m generator is the classic transient-equilibrium system. This matters at the bench: once equilibrium is reached, the Tc-99m available on the column falls at the Mo-99 rate (about 78% remains after 24 hours, per the TechneLite label), which is why generator yield drops day by day.

Why the other choices don't fit

  • B: A shorter-lived daughter is exactly the case where equilibrium can form. The daughter falls to zero only if the parent is gone or the daughter outlives the parent.
  • C: Isomeric transition is how Tc-99m decays, not a type of equilibrium. The daughter's decay mode doesn't control how fast the parent decays.
  • D: Secular equilibrium needs a daughter half-life that is much shorter than the parent's, so the activities become essentially equal. A factor of about 11 isn't enough for that label.

Source: IAEA, Nuclear Medicine Physics: A Handbook for Teachers and Students (2014), Chapter 1, section 1.4.3, Equilibrium in parent–daughter activities; DailyMed, TechneLite (technetium Tc 99m generator) label, Physical Characteristics (Mo-99 66 h; Tc-99m 6.02 h; 78% Mo-99 remains after 24 h)

Question 7 of 50

III. Pharmaceutical and Radiopharmaceutical Agents · NMTCB-007

A Tc-99m generator was eluted at 05:30. At 17:45 the same day, a technologist wants to use the leftover eluate to prepare an add-on kit. What does the TechneLite label say?

  • A. Use it, because the eluate can be used for up to 24 hours after elution
  • B. Don't use it, because the eluate shouldn't be used more than 12 hours after elution
  • C. Use it, because only the prepared kits carry an expiration time, not the generator eluate itself
  • D. Use it only if a new Mo-99 assay shows the eluate still meets the limit
Show answer and explanation

Correct answer: B. The TechneLite label states that sodium pertechnetate Tc 99m eluate shouldn't be used later than 12 hours after the time of elution. 05:30 to 17:45 is 12 hours 15 minutes, so the eluate is past its use time. The label ties this limit to the fact that the eluate contains no antimicrobial agent. The fix is a fresh elution if the generator has enough yield, or a unit dose from the radiopharmacy.

Why the other choices don't fit

  • A: The label limit is 12 hours, not 24.
  • C: The eluate itself carries a 12-hour expiration. Prepared kits have separate expirations on top of that.
  • D: A repeat Mo-99 assay doesn't extend the 12-hour use limit. The eluate is out of date no matter what the assay shows.

Source: DailyMed, TechneLite (technetium Tc 99m generator) label, Description and Dosage and Administration (eluate has no antimicrobial agent; not to be used after 12 hours from elution)

Question 8 of 50

V. Clinical Procedures · NMTCB-008

A patient receives DaTscan (ioflupane I 123) at 10:00 after an appropriate thyroid blocking agent. According to the label, what is the imaging window?

  • A. SPECT at 10:00 the next day, 24 hours after injection, and no earlier
  • B. Planar whole-body imaging at 14:00, then again at 10:00 the next day
  • C. SPECT between 10:15 and 11:00, which is 15 to 60 minutes after injection
  • D. SPECT between 13:00 and 16:00, which is 3 to 6 hours after injection
Show answer and explanation

Correct answer: D. The DaTscan label gives 111 to 185 MBq (3 to 5 mCi) intravenously over at least 20 seconds, a thyroid blocking agent at least 1 hour before the dose, and SPECT imaging beginning between 3 and 6 hours after injection. An injection at 10:00 therefore puts the imaging window from 13:00 to 16:00. Scheduling the camera and the patient around that window is part of the technologist's job.

Why the other choices don't fit

  • A: 24 hours is outside the labeled 3-to-6-hour window.
  • B: DaTscan imaging is SPECT of the brain, not planar whole-body imaging, and there's no labeled next-day image.
  • C: 15 to 60 minutes is far too early. The label's window starts at 3 hours.

Source: DailyMed, DaTscan (ioflupane I 123) label, Highlights and sections 2.2 to 2.4 (111–185 MBq over at least 20 seconds; thyroid blockade; SPECT 3 to 6 hours post injection)

Question 9 of 50

V. Clinical Procedures · NMTCB-009

An Amyvid (florbetapir F 18) PET scan is ordered. Which administration and imaging plan follows the label?

  • A. 74 MBq (2 mCi) by slow infusion, and whole-body PET starting 3 hours later with arms raised
  • B. 370 MBq (10 mCi) IV over 10 minutes, then a 60-minute dynamic PET acquisition starting the next day
  • C. 185 MBq (5 mCi) IV bolus, and planar gamma camera images of the brain at 2 and 4 hours
  • D. 370 MBq (10 mCi) IV bolus, a 10 mL saline flush, and a 10-minute PET scan starting about 30 to 50 minutes later
Show answer and explanation

Correct answer: D. The Amyvid label recommends 370 MBq (10 mCi) as a single intravenous bolus in a total volume of up to 10 mL, followed by an intravenous flush of about 10 mL of 0.9% sodium chloride. It calls for a 10-minute PET image starting approximately 30 to 50 minutes after administration. F-18 has a physical half-life of 109.8 minutes, so the dose delivery time has to be coordinated with scanner availability. The label also says Amyvid images should be interpreted only by readers who have completed the manufacturer's training program.

Why the other choices don't fit

  • A: The dose is too low and the imaging too late, and amyloid PET is a brain study, not whole body.
  • B: The label calls for a bolus and a 10-minute image soon after, not a slow injection and next-day imaging, which F-18 decay wouldn't allow.
  • C: Florbetapir is a PET agent, so planar gamma camera imaging isn't used, and the dose doesn't match the label.

Source: DailyMed, Amyvid (florbetapir F 18) label, Highlights and sections 2.2 to 2.4 (370 MBq bolus up to 10 mL; 10 mL saline flush; 10-minute PET at 30 to 50 minutes; reader training) and section 11 (F-18 half-life 109.8 minutes)

Question 10 of 50

IV. Instrument Operations and Quality Control · NMTCB-010

A technologist measures the Cs-137 check source on the Tc-99m setting of the dose calibrator each morning. The displayed 'activity' doesn't match the Cs-137 source's true activity. What does this mean?

  • A. The dose calibrator is broken, since every setting should read a check source's true activity
  • B. Nothing by itself; the reading is compared with previous daily results, and a change from those is the warning sign
  • C. The Tc-99m setting should be skipped from now on, since check sources are only measured on the Cs-137 setting
  • D. The check source is leaking, because a mismatch on the Tc-99m setting signals contamination
Show answer and explanation

Correct answer: B. The IAEA handbook describes daily check-source testing with a long-lived source, such as Co-57 or Cs-137 shaped to mimic a vial, measured on every radionuclide setting used clinically. It points out that the reading of a Cs-137 source on the Tc-99m setting won't be a correct measurement of its activity, because the setting applies a calibration factor meant for Tc-99m. What matters is whether the reading falls within the range expected from previous results. A reading outside that range may indicate a faulty dose calibrator or a change in the Tc-99m calibration factor. The same section calls for measuring and recording background each morning before use and confirming that no extra background is present before each assay.

Why the other choices don't fit

  • A: Each setting applies a nuclide-specific calibration factor, so a Cs-137 source isn't expected to read its true activity on the Tc-99m setting.
  • C: The handbook calls for measuring the check source on all clinically used settings, so the Tc-99m setting is included.
  • D: A leak is found with a wipe (leak) test, not by comparing a dial setting with the source's activity.

Source: IAEA, Nuclear Medicine Physics: A Handbook for Teachers and Students (2014), Chapter 9, section 9.2.2.1, Background, and section 9.2.2.2, Check source reproducibility

Question 11 of 50

III. Pharmaceutical and Radiopharmaceutical Agents · NMTCB-011

A technologist is preparing a Tc-99m sestamibi kit. The pertechnetate has been added and the vial shaken. According to the sestamibi kit label, what comes next?

  • A. Heat it in a boiling water bath for 10 minutes, timed from when the water returns to a boil
  • B. Freeze it for 10 minutes to stabilize the complex, then warm it to room temperature
  • C. Heat it in a dry heating block at 50°C for 30 minutes, then cool it in an ice bath
  • D. Let it stand at room temperature for 15 minutes, then check radiochemical purity before use
Show answer and explanation

Correct answer: A. The sestamibi kit label directs that, after adding sodium pertechnetate Tc 99m and shaking, the vial is placed upright in a boiling water bath, boiled for 10 minutes (timed from when the water begins to boil again), then removed to a lead shield and allowed to cool for 15 minutes. The product should be used within 6 hours after preparation, and the label notes that product with radiochemical purity of at least 90% was used in the clinical trials. Tetrofosmin (Myoview) is the useful contrast: it's prepared at room temperature, with a 15-minute incubation and no boiling step.

Why the other choices don't fit

  • B: Freezing isn't part of sestamibi preparation. The complex forms with heat.
  • C: The sestamibi label specifies a boiling water bath, not a 50°C dry block. Lower heat may not complete the labeling reaction.
  • D: A room-temperature 15-minute incubation describes tetrofosmin (Myoview), not sestamibi.

Source: DailyMed, Kit for the Preparation of Technetium Tc99m Sestamibi label, section 2.3, Instructions for Preparation, Boiling Water Bath Procedure, steps g and h (10 minutes; cool 15 minutes; use within 6 hours); DailyMed, Myoview (tetrofosmin) label, Dosage and Administration, preparation (room temperature, 15 minutes)

Question 12 of 50

V. Clinical Procedures · NMTCB-012

A patient is scheduled for Pylarify (piflufolastat F 18) PSMA PET/CT. What does the label say about the patient and the acquisition?

  • A. Hydrate well, void right before imaging, start about 60 minutes after injection, and scan from mid-thigh to vertex
  • B. Stop all fluids for 4 hours, start imaging the next morning, and scan from the vertex to mid-thigh
  • C. Fast for 12 hours, start imaging 10 minutes after injection, and scan from the vertex down to the toes
  • D. Keep the bladder full for the scan, start about 3 hours after injection, and image only the pelvis
Show answer and explanation

Correct answer: A. The Pylarify label recommends 333 MBq (9 mCi), with an acceptable range of 296 to 370 MBq (8 to 10 mCi), as an intravenous bolus. Patients should drink water to be well hydrated before the dose and keep drinking and voiding often for the first few hours to reduce radiation exposure. Imaging starts about 60 minutes after injection, the patient voids immediately before imaging, and acquisition starts at mid-thigh and proceeds to the vertex of the skull. Starting at mid-thigh means the pelvis is imaged first, soon after the patient has voided.

Why the other choices don't fit

  • B: Withholding fluids goes against the label's hydration instructions, and F-18 decay rules out next-morning imaging.
  • C: The label doesn't call for a 12-hour fast, 10 minutes is too early, and the range runs from mid-thigh to vertex.
  • D: A full bladder would obscure the pelvis, and the label calls for voiding before imaging and starting at about 60 minutes.

Source: DailyMed, Pylarify (piflufolastat F 18) label, Highlights, sections 2.2 to 2.4 (333 MBq; hydration and voiding; imaging about 60 minutes; mid-thigh to skull vertex)

Question 13 of 50

II. Radiation Safety and Regulations · NMTCB-013

An inpatient who received I-131 therapy can't yet be released under 10 CFR 35.75. The patient's adult daughter wants to visit. Under NRC rules, what dose may the licensee allow this visitor to receive?

  • A. No more than 0.002 rem (0.02 mSv) in any one hour, with no annual cap for this visitor
  • B. No more than 0.1 rem (1 mSv), with no exception allowed for visitors of hospitalized patients
  • C. Up to 5 rem (50 mSv), the same annual limit that applies to occupational radiation workers
  • D. Up to 0.5 rem (5 mSv), if the authorized user decides before the visit that it is appropriate
Show answer and explanation

Correct answer: D. The general public dose limit in 10 CFR 20.1301(a)(1) is 0.1 rem (1 mSv) per year. Paragraph (c) of the same section makes a specific exception for visitors of a patient who can't be released under 35.75: the licensee may let such a visitor receive more than 0.1 rem, up to 0.5 rem (5 mSv), if the authorized user has determined before the visit that it is appropriate. In practice the technologist's job is to know that the authorized user's decision has to come first, and that time and distance instructions for the visitor still apply under ALARA. This differs from the release rule for patients sent home, where 35.75 allows release if the dose to any other person is not likely to exceed 0.5 rem.

Why the other choices don't fit

  • A: 0.002 rem in any one hour is the dose-rate limit for unrestricted areas in 20.1301(a)(2). It doesn't define what a visitor may receive overall.
  • B: 0.1 rem is the default public limit, but 20.1301(c) creates an exception of up to 0.5 rem for visitors of patients who can't be released.
  • C: 5 rem is the annual occupational limit for adult radiation workers. A family visitor is a member of the public, not an occupationally exposed worker.

Source: eCFR, 10 CFR 20.1301, Dose limits for individual members of the public, paragraphs (a) and (c); eCFR, 10 CFR 35.75, Release of individuals containing unsealed byproduct material, paragraph (a)

Question 14 of 50

V. Clinical Procedures · NMTCB-014

A Ga-68 dotatate (Netspot) PET scan is being planned for a patient with a neuroendocrine tumor. What acquisition does the label call for?

  • A. A planar whole-body sweep on a gamma camera at 4 and 24 hours after injection
  • B. A head-only acquisition started 4 hours after injection, to give the background time to clear
  • C. A dynamic chest acquisition started at the moment of injection and lasting 6 hours
  • D. A whole-body acquisition from skull to mid-thigh, acquired 40 to 90 minutes after injection
Show answer and explanation

Correct answer: D. The Netspot label says the PET acquisition must include a whole-body acquisition from skull to mid-thigh, and that images can be acquired 40 to 90 minutes after intravenous administration of gallium Ga 68 dotatate. It also lets sites adjust the acquisition delay and duration for their equipment and for the patient and tumor, to get the best image quality. Ga-68 has a half-life of 68 minutes, according to the label, which is why the window is short compared with In-111 pentetreotide, which is imaged on a gamma camera at much later time points.

Why the other choices don't fit

  • A: 4- and 24-hour planar imaging fits In-111 pentetreotide on a gamma camera, not a Ga-68 PET study.
  • B: Ga-68 decays too fast for a 4-hour delay, and the study is whole body, not head only.
  • C: The label calls for whole-body imaging in a 40-to-90-minute window, not a 6-hour dynamic chest study.

Source: DailyMed, Netspot (kit for gallium Ga 68 dotatate) label, section 2.6, Image Acquisition (skull to mid-thigh; 40 to 90 minutes post injection) and radiation dosimetry section (Ga-68 half-life 68 minutes)

Question 15 of 50

III. Pharmaceutical and Radiopharmaceutical Agents · NMTCB-015

A Tc-99m MAA vial holds 50 mCi in 5.0 mL at calibration time and contains 3.0 million particles. A 4.0 mCi dose is drawn at calibration time. About how many particles will the patient receive?

  • A. 600,000 particles
  • B. 120,000 particles
  • C. 240,000 particles
  • D. 400,000 particles
Show answer and explanation

Correct answer: C. The activity concentration is 50 mCi ÷ 5.0 mL = 10 mCi/mL, so a 4.0 mCi dose is 0.40 mL. The particle concentration is 3.0 million ÷ 5.0 mL = 600,000 particles/mL, so 0.40 mL contains 0.40 × 600,000 = 240,000 particles. A shortcut gives the same result: the dose is 4/50 = 8% of the vial, and 8% of 3.0 million is 240,000. The Pulmotech MAA label recommends 1 to 4 mCi with 200,000 to 700,000 particles for an adult lung perfusion study, so 240,000 is in range. The label lists severe pulmonary hypertension as a contraindication and advises the lowest possible number of particles in patients with pulmonary hypertension. Timing changes the math: as the vial decays, a given mCi takes more volume, and therefore more particles, so the particle check should be redone for doses drawn later in the day.

Why the other choices don't fit

  • A: 600,000 is the number of particles in 1 mL, not in the 0.4 mL dose.
  • B: 120,000 is half the right answer. It results from using 10 mL as the vial volume or halving the particle count.
  • D: 400,000 treats the dose as 0.4 mL with 1 million particles per mL, which doesn't match this vial.

Source: DailyMed, Pulmotech MAA (technetium Tc 99m albumin aggregated) label, Highlights and section 2.3, Dosage and Administration (adults 1 to 4 mCi, 200,000 to 700,000 particles; particles per vial on the vial label)

Question 16 of 50

IV. Instrument Operations and Quality Control · NMTCB-016

A survey meter's daily constancy reading on its long-lived reference source is 14% lower than its usual value after correcting for source decay. The battery check passes. What should happen next, per the IAEA handbook?

  • A. Keep using the meter as it is, since the battery check is the only daily test that really matters
  • B. Raise the alarm threshold by 14% so future readings line up with the reference
  • C. Use the meter only for high-activity areas, where small errors don't matter
  • D. Have the meter recalibrated, because day-to-day constancy readings should agree within 10%
Show answer and explanation

Correct answer: D. The IAEA handbook lists daily survey meter checks: a battery check, a background reading in an area away from radioactive sources to show the meter isn't contaminated, and a constancy check with a long-lived reference source in a reproducible geometry. Aside from decay of the reference source, the day-to-day readings should agree within 10%; if they don't, the meter should be recalibrated. A 14% drop fails that criterion. Separately, NRC rules in 10 CFR 35.61 bar using a meter for compliance when its indicated rate differs from the calculated rate by more than 20% at calibration.

Why the other choices don't fit

  • A: Battery status is only one of the daily checks. A failed constancy check means the meter's response has changed.
  • B: Adjusting thresholds to hide a response change defeats the purpose of the constancy check.
  • C: A meter with an unknown response problem isn't reliable in any area, and high-dose-rate areas are where accuracy matters most.

Source: IAEA, Nuclear Medicine Physics: A Handbook for Teachers and Students (2014), Chapter 10, section 10.5.2, Survey meter; eCFR, 10 CFR 35.61, Calibration of survey instruments, paragraph (b)

Question 17 of 50

V. Clinical Procedures · NMTCB-017

An In-111 pentetreotide (Octreoscan) study will include SPECT. Which preparation and dose follow the label?

  • A. 37 MBq (1 mCi), no special preparation, and imaging 30 minutes after the injection
  • B. 111 MBq (3 mCi), a clear-liquid diet for 3 days, and no laxative, since bowel activity helps
  • C. 222 MBq (6 mCi), good hydration, and a mild laxative from the evening before for 48 hours
  • D. 222 MBq (6 mCi), fluid restriction for 24 hours, and an enema right before imaging
Show answer and explanation

Correct answer: C. The Octreoscan label recommends 111 MBq (3 mCi) for planar imaging and 222 MBq (6 mCi) for SPECT. Patients should be well hydrated before the dose and drink liberally afterward, which flushes unbound labeled pentetreotide through the kidneys and lowers radiation dose. A mild laxative such as bisacodyl or lactulose is recommended starting the evening before administration and continuing for 48 hours, to reduce bowel activity that can obscure abdominal findings. The label also says the prepared product must be tested for labeling yield and used within 6 hours.

Why the other choices don't fit

  • A: 37 MBq is well below the labeled dose, and 30 minutes is far too early for In-111 pentetreotide imaging.
  • B: 111 MBq is the planar dose, not the SPECT dose, and the label recommends a laxative because bowel activity interferes with reading the images.
  • D: The label stresses hydration, not fluid restriction, and the laxative regimen starts the evening before.

Source: DailyMed, Octreoscan (indium In 111 pentetreotide) label, Dosage and Administration (111 MBq planar; 222 MBq SPECT; hydration; mild laxative evening before for 48 hours) and Precautions

Question 18 of 50

I. Radiation Physics and Detection · NMTCB-018

A technologist wants a single count from a sample to have a fractional standard deviation of 2% (one standard deviation). Assuming Poisson counting statistics and negligible background, about how many counts must be collected?

  • A. 50 counts
  • B. 2,500 counts
  • C. 10,000 counts
  • D. 5,000 counts
Show answer and explanation

Correct answer: B. For a Poisson process, the standard deviation of a single measurement of N counts is estimated as the square root of N, so the fractional standard deviation is √N ÷ N, which simplifies to 1 ÷ √N. Setting 1 ÷ √N equal to 0.02 gives √N = 50, so N = 2,500 counts. The IAEA handbook treats this as the core way to estimate the precision of a single measurement and notes the fractional standard deviation is the key indicator of precision. The habit to build is working backward from the precision you want: halving the fractional error takes four times the counts. That is why 1% precision needs 10,000 counts, and why short counts on low-activity wipe samples are so noisy.

Why the other choices don't fit

  • A: 50 is the square root of the answer, not the count. With 50 counts, the fractional standard deviation would be 1 ÷ √50, about 14%.
  • C: 10,000 counts gives 1% precision (√10,000 = 100, and 100 ÷ 10,000 = 1%), which is twice as tight as the 2% asked for.
  • D: Doubling 2,500 doesn't follow from the square-root relationship. 5,000 counts gives about 1.4%, better than needed but not the minimum.

Source: IAEA, Nuclear Medicine Physics: A Handbook for Teachers and Students (2014), Chapter 5, sections 5.3.3 (Poisson distribution) and 5.4, Estimation of the precision of a single measurement

Question 19 of 50

III. Pharmaceutical and Radiopharmaceutical Agents · NMTCB-019

Why does Tc-99m MAA show lung perfusion on images taken soon after intravenous injection?

  • A. The particles dissolve in the blood and the albumin is taken up by alveolar macrophages
  • B. The particles bind to red cells, which concentrate in the pulmonary veins in proportion to flow
  • C. Most particles are 10 to 90 µm across and lodge in pulmonary arterioles and capillaries
  • D. The particles are inhaled from the bloodstream into the airways and stay in the alveoli
Show answer and explanation

Correct answer: C. The Pulmotech MAA label describes particles with at least 90% between 10 and 90 micrometers and none larger than 150 micrometers. After intravenous injection, more than 90% of the particles are trapped in the arterioles and capillaries of the lungs within 1 to 5 minutes, and the label states that their distribution in the lungs is a function of regional pulmonary blood flow. That trapping in the first capillary bed is the mechanism, which is why areas with no flow, such as those beyond a pulmonary embolus, appear as defects. The aggregates are fragile, so the micro-occlusion is temporary: erosion and fragmentation let the pieces pass through the capillary bed to the reticuloendothelial system, and lung clearance has a biological half-life of about 10.8 hours.

Why the other choices don't fit

  • A: Fragments do end up in the reticuloendothelial system hours later, but the early lung images reflect particles trapped in capillaries, not uptake by alveolar macrophages.
  • B: MAA isn't a red cell label, and the particles lodge on the arterial side of the pulmonary circulation, not in the veins.
  • D: Particles injected into a vein stay in the blood vessels. Showing airways requires an inhaled agent such as Xe-133 gas or a DTPA aerosol.

Source: DailyMed, Pulmotech MAA (technetium Tc 99m albumin aggregated) label, section 11, Description (particle size) and section 12, Clinical Pharmacology (trapping within 1 to 5 minutes; distribution follows regional blood flow; biological half-life 10.8 hours)

Question 20 of 50

V. Clinical Procedures · NMTCB-020

On a normal In-111 oxyquinoline labeled leukocyte scan, where does the label say most of the activity goes after injection?

  • A. About 30% to the spleen and about 30% to the liver, plateauing from about 2 to 48 hours
  • B. Mostly to the lungs, where nearly all of it stays for the whole 72 hours of imaging
  • C. Mostly to the kidneys and bladder, with nearly all of it cleared in the urine by 4 hours
  • D. Mostly to the thyroid and stomach, from free indium released from the labeled cells
Show answer and explanation

Correct answer: A. The Indium In 111 Oxyquinoline label reports that after labeled leukocytes were injected into normal volunteers, about 30% of the dose went to the spleen and about 30% to the liver, reaching a plateau from 2 to 48 hours after injection, with no significant clearance observed at 72 hours. Knowing this normal pattern helps the technologist judge whether an image looks technically sound before abnormal sites of infection are read. The same label warns that plasma and red cell contamination impair labeling and that labeled cells should be used within one hour if possible and never more than three hours after preparation.

Why the other choices don't fit

  • B: The label describes the spleen and liver as the main sites of uptake, with a plateau from 2 to 48 hours, not the lungs.
  • C: Renal and bladder clearance describes many small-molecule tracers. Labeled leukocytes go mainly to the spleen and liver, with little early urinary clearance.
  • D: Thyroid and stomach uptake are signs of free pertechnetate, not of In-111 labeled leukocytes.

Source: DailyMed, Indium In 111 Oxyquinoline label (GE Healthcare), Clinical Pharmacology (about 30% spleen and 30% liver; plateau 2 to 48 hours; no significant clearance at 72 hours)

Question 21 of 50

II. Radiation Safety and Regulations · NMTCB-021

A package of radiopharmaceuticals is surveyed for shipping. The maximum reading at the package surface is 12 mrem/h, and the maximum reading 1 meter from the surface is 0.4 mrem/h. Which DOT label category applies?

  • A. RADIOACTIVE YELLOW-II, because the transport index is 0.4 and the surface reading is above 0.5 mrem/h
  • B. RADIOACTIVE WHITE-I, because the reading at 1 meter is less than 1 mrem/h for this package
  • C. No label, because packages under 50 mrem/h at the surface are excepted from all labeling
  • D. RADIOACTIVE YELLOW-III, because any package with a surface reading above 10 mrem/h needs this label category
Show answer and explanation

Correct answer: A. The transport index (TI) is the maximum radiation level at 1 meter from the package surface in mrem/h (or the mSv/h value multiplied by 100), so this package has a TI of 0.4. Under 49 CFR 172.403, WHITE-I requires a TI of 0 and a surface reading of 0.5 mrem/h or less. YELLOW-II covers a TI above 0 but not more than 1 and a surface reading above 0.5 mrem/h but no more than 50 mrem/h. YELLOW-III covers a TI above 1 up to 10 or a surface reading above 50 mrem/h up to 200 mrem/h. Both measurements point to YELLOW-II here. The rule is to apply the highest category required by either condition; the regulation's own example is a package with a TI of 0.8 and a surface reading of 60 mrem/h, which must carry YELLOW-III because of its surface reading.

Why the other choices don't fit

  • B: WHITE-I requires a TI of 0 and a surface reading of 0.5 mrem/h or less. A TI of 0.4 and a surface reading of 12 mrem/h both exceed WHITE-I.
  • C: Excepted packages are covered by separate rules with much lower limits (for example 0.5 mrem/h at the surface for limited quantities). 50 mrem/h is the top of the YELLOW-II surface range.
  • D: YELLOW-III starts at a TI above 1 or a surface reading above 50 mrem/h. Neither applies to this package.

Source: eCFR, 49 CFR 173.403, Definitions (transport index), definition of Transport index; eCFR, 49 CFR 172.403, Class 7 (radioactive) material labels, paragraphs (b) and (c), label category table; eCFR, 49 CFR 173.421, Excepted packages for limited quantities of Class 7 materials, paragraph (b)

Question 22 of 50

V. Clinical Procedures · NMTCB-022

A patient with suspected stroke received Tc-99m bicisate (Neurolite) for brain perfusion SPECT. What does the label say about imaging time?

  • A. Images should start at 4 hours and must be finished within 30 minutes of starting
  • B. Images can be obtained from 10 minutes to 6 hours after injection, with optimal images at 30 to 60 minutes
  • C. Images must be started within 2 minutes of injection, or the brain activity washes out completely before scanning
  • D. Images are best at 24 hours, after background activity has cleared from the blood
Show answer and explanation

Correct answer: B. The Neurolite label explains that Tc-99m bicisate crosses intact cell membranes and the blood-brain barrier by passive diffusion, that the amount in the brain is stable until about 6 hours, and that after background clearance, brain images can be obtained from 10 minutes to 6 hours after injection, with optimal images 30 to 60 minutes after injection. About 5% of the injected dose remains in the blood at one hour, and the tracer clears mainly through the kidneys.

Why the other choices don't fit

  • A: The label doesn't require a 4-hour wait or a 30-minute limit. Optimal images are at 30 to 60 minutes.
  • C: Bicisate brain activity is stable for hours. A 2-minute start isn't required.
  • D: 24 hours is outside the labeled window, and Tc-99m decay would leave little usable activity.

Source: DailyMed, Neurolite (bicisate) label, Clinical Pharmacology (brain activity stable until about 6 hours; images 10 minutes to 6 hours; optimal 30–60 minutes)

Question 23 of 50

IV. Instrument Operations and Quality Control · NMTCB-023

A NaI(Tl) detector's Tc-99m photopeak (140 keV) has a full width at half maximum of 14.7 keV. What is the energy resolution?

  • A. About 10.5%
  • B. About 14.7%
  • C. About 21.0%
  • D. About 9.5%
Show answer and explanation

Correct answer: A. Energy resolution is the full width at half maximum (FWHM) of the photopeak divided by the photopeak energy, expressed as a percentage. Here that is 14.7 keV ÷ 140 keV = 0.105, or about 10.5%. The IAEA handbook defines observed energy resolution this way (ΔE ÷ E). Smaller percentages mean better resolution, because the detector separates photopeak events more cleanly from lower-energy scattered photons.

Why the other choices don't fit

  • B: 14.7 is the FWHM in keV, not a percentage. It has to be divided by the photopeak energy.
  • C: 21.0% doubles the correct value, which is the error from using half the photopeak energy as the denominator.
  • D: 9.5 comes from dividing 140 by 14.7, which flips the ratio. The FWHM goes on top and the photopeak energy on the bottom.

Source: IAEA, Nuclear Medicine Physics: A Handbook for Teachers and Students (2014), Chapter 6, section 6.1, eq. (6.1), energy resolution FWHM divided by E

Question 24 of 50

III. Pharmaceutical and Radiopharmaceutical Agents · NMTCB-024

A Tc-99m sulfur colloid kit is being prepared. After the reagents are added, how does the label direct heating?

  • A. Microwave the vial for 1 minute at full power, then cool it right away under running water
  • B. Keep the vial at room temperature, because boiling a colloid makes the particles dissolve
  • C. Heat the vial in a boiling water bath for 30 minutes so the particles grow large enough to trap
  • D. Place the vial in a vigorously boiling water bath for 5 minutes, then let it cool for 3 minutes
Show answer and explanation

Correct answer: D. The sulfur colloid kit label directs placing the reaction vial in a vigorously boiling water bath deep enough to cover the liquid for five minutes, then moving it to a lead shield to cool for three minutes. Solution B is then added, and the preparation is allowed to cool to body temperature before use. Timing matters: heating too long or using a weak boil changes the particle size, which changes where the colloid goes in the body (liver, spleen, marrow or lymphatics).

Why the other choices don't fit

  • A: The label doesn't permit microwave heating, and rapid cooling under water isn't the labeled method.
  • B: Sulfur colloid formation needs heat. Skipping the boiling step would leave the colloid incomplete.
  • C: Heating for 30 minutes would form overly large particles. The label specifies 5 minutes.

Source: DailyMed, Kit for the Preparation of Technetium Tc99m Sulfur Colloid label, Directions for Preparation (vigorously boiling water bath for five minutes; cool three minutes; add Solution B; cool to body temperature)

Question 25 of 50

V. Clinical Procedures · NMTCB-025

A breast surgeon wants Lymphoseek (Tc-99m tilmanocept) injected at 16:00 the day before a 09:00 sentinel node biopsy. What does the label say about this plan?

  • A. It doesn't fit, because the label requires the injection to be given less than 15 minutes before the incision
  • B. It fits, because Lymphoseek may be injected any time up to 48 hours before mapping begins
  • C. It doesn't fit, because procedures should be completed within 15 hours of injection, and this gap is 17 hours
  • D. It fits, as long as the injection is at least 15 minutes before surgery, with no upper limit
Show answer and explanation

Correct answer: C. The Lymphoseek label recommends 18.5 MBq (0.5 mCi) and 50 mcg, given at least 15 minutes before starting intraoperative lymphatic mapping and sentinel node biopsy, with those procedures completed within 15 hours after the injection. 16:00 one day to 09:00 the next is 17 hours, so a surgery starting at 09:00 would already be outside the window. A same-day injection, or one late enough the evening before that surgery finishes within 15 hours, would fit. The label also lists intradermal, subcutaneous, subareolar or peritumoral injection routes and says the radiolabeled product should be used within 6 hours of preparation.

Why the other choices don't fit

  • A: The label requires at least 15 minutes before mapping, not less than 15 minutes.
  • B: The label window is 15 hours from injection to completion, not 48 hours.
  • D: 15 minutes is the minimum lead time. The label also sets an upper limit of 15 hours.

Source: DailyMed, Lymphoseek (technetium Tc 99m tilmanocept) label, Highlights and section 2.2, Recommended Dosing (18.5 MBq; at least 15 minutes before; complete within 15 hours)

Question 26 of 50

V. Clinical Procedures · NMTCB-026

A Tc-99m MAA perfusion study is finished, and the physician now wants Tc-99m DTPA aerosol ventilation images. Per the DTPA label, what count rate should the technologist aim for during the aerosol ventilation imaging?

  • A. About three times the count rate of the perfusion images, so the ventilation counts dominate
  • B. The same count rate as the perfusion images, so the two sets can be subtracted
  • C. A fixed 5,000 counts per minute, no matter what the perfusion count rate was
  • D. About half the count rate of the perfusion images, to keep the patient's radiation dose as low as possible
Show answer and explanation

Correct answer: A. When ventilation is imaged after perfusion, both studies use Tc-99m, so residual MAA activity in the lungs shows up on the ventilation images. The DTPA label's aerosol table states that for lung imaging performed after perfusion imaging, the target count rate should be approximately three times the perfusion count rate. When ventilation is done before perfusion, the label instead gives a target of 3 to 5 minutes of inhalation or an imaging count rate of 50,000 to 100,000 counts per minute. The adult nebulizer load is 925 to 1,850 MBq (25 to 50 mCi) to deliver about 18.5 to 37 MBq (0.5 to 1.0 mCi) to the lungs.

Why the other choices don't fit

  • B: Matching count rates would make the two studies hard to tell apart. The label calls for about three times the perfusion rate.
  • C: The label's fixed range (50,000 to 100,000 counts per minute) applies when ventilation comes first, and 5,000 counts per minute is far below it.
  • D: A lower count rate would let the residual perfusion activity dominate the ventilation images.

Source: DailyMed, Draximage DTPA (technetium Tc 99m pentetate) label, Table 3, Aerosol Inhalation Administration (target count rate about three times perfusion; 50,000 to 100,000 per minute when done first)

Question 27 of 50

III. Pharmaceutical and Radiopharmaceutical Agents · NMTCB-027

A technologist is labeling red cells in vitro with an UltraTag RBC kit. The patient's blood was collected into a syringe containing too much ACD anticoagulant. What does the label warn could happen?

  • A. Labeling efficiency may drop, because excess ACD lowers the tag yield
  • B. Nothing changes, because the amount of anticoagulant doesn't affect labeling
  • C. Free pertechnetate will rise only if the blood sits longer than 24 hours
  • D. The cells may clot in the syringe, because ACD in excess acts as a coagulant
Show answer and explanation

Correct answer: A. The UltraTag RBC label describes labeling 1.0 to 3.0 mL of whole blood anticoagulated with heparin or ACD. It states that labeling efficiency can decrease in the presence of excess ACD, apparently because excess ACD impairs the diffusion of stannous ion across the red cell membrane, so ACD shouldn't exceed 0.15 mL per mL of blood. Stannous ion has to get inside the red cells to reduce the pertechnetate there; sodium hypochlorite then oxidizes the stannous ion left outside the cells. Lower labeling efficiency shows up as free pertechnetate on images (thyroid, stomach and salivary glands), which can mimic or hide pathology on blood pool and GI bleeding studies.

Why the other choices don't fit

  • B: The label specifically limits ACD volume because it affects labeling.
  • C: Excess ACD acts on the labeling step itself, by slowing stannous ion entry into the cells. The problem doesn't depend on how long the blood sits.
  • D: ACD is an anticoagulant whatever its volume. The concern with excess ACD is lower labeling efficiency, not clotting.

Source: DailyMed, UltraTag RBC label, Clinical Pharmacology (excess ACD can decrease labeling efficiency; not more than 0.15 mL ACD per mL of blood)

Question 28 of 50

IV. Instrument Operations and Quality Control · NMTCB-028

A Geiger counter was calibrated for exposure rate using a Cs-137 source. A technologist then uses it to estimate the exposure rate near a patient who received Tl-201. Why does the IAEA handbook warn that this reading may be inaccurate?

  • A. Geiger counters respond only to beta particles, so photons from Tl-201 aren't counted at all
  • B. Geiger counters can't detect photons below 662 keV at all, so a Tl-201 patient would read zero on the meter
  • C. Geiger counters always over-read by exactly a factor of 2 for any nuclide other than Cs-137
  • D. Geiger pulses are the same size regardless of photon energy, so calibration holds only for the calibrating radionuclide
Show answer and explanation

Correct answer: D. The IAEA handbook explains that both cutie-pie ionization chambers and Geiger counters are generally calibrated for exposure rate. For an ionization chamber, the signal depends on the energy of the detected photons, so it relates directly to exposure for all radionuclides. In a Geiger counter, every pulse has the same amplitude regardless of the energy of the incoming radiation, so the calibration applies only to the radionuclide(s) used to calibrate it. Geiger counters are very sensitive, which makes them well suited to low-level contamination surveys, while the low-sensitivity cutie-pie is designed for higher photon fluxes and gives better exposure-rate readings across energies.

Why the other choices don't fit

  • A: Geiger counters do detect photons. Their limitation is the energy-independent pulse height, not blindness to gamma rays.
  • B: Geiger counters detect low-energy photons. The issue is that their response per unit exposure varies with energy.
  • C: There's no single fixed correction factor. The error depends on the photon energies involved.

Source: IAEA, Nuclear Medicine Physics: A Handbook for Teachers and Students (2014), Chapter 10, section 10.4.1, Survey meters

Question 29 of 50

V. Clinical Procedures · NMTCB-029

Before a Xe-133 ventilation study, a technologist notices that the delivery system was loaded with Xe-133 and has been sitting for 20 minutes waiting for the patient. What warning does the Xe-133 label give that applies here?

  • A. Xe-133 adheres to some plastics and rubber, so it shouldn't stand in tubing, and the loss may make the study nondiagnostic
  • B. Xe-133 settles to the bottom of the tubing as a liquid, so the system must be shaken before use
  • C. Xe-133 decays so fast that 20 minutes would leave almost nothing, since its half-life is under an hour
  • D. Xe-133 reacts chemically with oxygen in the tubing to form a solid that blocks the delivery system
Show answer and explanation

Correct answer: A. The Xe-133 gas label warns that delivery systems, such as respirators or spirometers, and their tubing must be leakproof so radioactivity isn't lost into lab areas not protected by exhaust systems. It also warns that Xe-133 adheres to some plastics and rubber and shouldn't be allowed to stand in tubing or respirator containers, because the loss of activity from that adherence may make the study nondiagnostic. Xe-133 has a physical half-life of 5.245 days and emits an 81 keV gamma photon, so decay over 20 minutes isn't the issue; adherence is.

Why the other choices don't fit

  • B: Xe-133 is delivered as a gas, not a liquid, and the problem is adherence to plastics and rubber.
  • C: Xe-133's half-life is 5.245 days. Twenty minutes of decay is negligible.
  • D: Xenon is a noble gas and doesn't form a solid with oxygen.

Source: DailyMed, Xenon Xe 133 gas label (Curium), Warnings (leakproof delivery systems; adheres to some plastics and rubber) and Physical Characteristics (5.245 days; 81.0 keV)

Question 30 of 50

II. Radiation Safety and Regulations · NMTCB-030

A department's Geiger survey meter, used to show compliance with NRC surveys, comes back from a repair of its detector cable. Its last calibration was four months ago. What does 10 CFR 35.61 require before the meter is used again?

  • A. Recalibrate it, because calibration is required after any repair that affects the calibration
  • B. Check only the battery and the background reading, since the repair didn't replace the Geiger tube itself
  • C. Replace it with a new meter, because repaired meters can't be used to show compliance
  • D. Use it as is until its annual calibration date, since that is what the rule requires
Show answer and explanation

Correct answer: A. 10 CFR 35.61 requires licensees to calibrate survey instruments used to show compliance before first use, annually, and following a repair that affects the calibration. A cable repair on the detector signal path can change the meter's response, so it must be recalibrated before it goes back into service. The rule also sets how: calibrate all scales with readings up to 1,000 mrem/h using a radiation source, check two separated readings on each scale used, and mark the calibration date on the instrument. A meter may not be used if the indicated exposure rate differs from the calculated rate by more than 20%. Daily battery, background and check-source readings (covered in the IAEA handbook) catch problems between calibrations but don't replace this calibration.

Why the other choices don't fit

  • B: Battery and background checks are daily operational checks. They don't verify that the meter reads exposure rates accurately after a repair.
  • C: Nothing in 35.61 bars repaired meters. A repaired meter can be used once it has been recalibrated.
  • D: Annual calibration is only one of three triggers. A repair that affects calibration requires a new calibration regardless of the date.

Source: eCFR, 10 CFR 35.61, Calibration of survey instruments, paragraphs (a) and (b); IAEA, Nuclear Medicine Physics: A Handbook for Teachers and Students (2014), Chapter 10, section 10.5.2, Survey meter

Question 31 of 50

I. Radiation Physics and Detection · NMTCB-031

F-18 decays by positron emission. After the positron slows down in tissue, it annihilates with an electron. What radiation do PET detectors use to locate that event?

  • A. The positron itself, detected directly as it leaves the patient's body surface
  • B. A single photon of 1.022 MeV, emitted along the positron's path of travel
  • C. Two photons of 0.511 MeV each, emitted together in the same direction
  • D. Two photons of 0.511 MeV each, traveling in nearly opposite directions
Show answer and explanation

Correct answer: D. Positron annihilation converts the rest mass of the positron and electron into two annihilation photons of 0.511 MeV each, emitted in opposite directions so that momentum is conserved. A PET scanner records a coincidence when two detectors on opposite sides of the ring register 511 keV photons within a short timing window, and it places the event along the line between them. The IAEA handbook describes annihilation as producing two oppositely directed quanta of 0.511 MeV, and notes that a small share of annihilations happen in flight, before the positron stops; those photon pairs aren't exactly equal in energy and don't always travel in exactly opposite directions.

Why the other choices don't fit

  • A: A positron travels only a short distance in tissue before it annihilates. It doesn't reach the detectors.
  • B: The total energy is 1.022 MeV, but it is split between two photons. A single photon couldn't conserve momentum when the pair is nearly at rest.
  • C: Photons emitted in the same direction would violate momentum conservation, and coincidence detection depends on the two photons striking opposite detectors.

Source: IAEA, Nuclear Medicine Physics: A Handbook for Teachers and Students (2014), Chapter 1, section 1.1.9, Annihilation quanta; Chapter 11, section 11.3.1, Principle of annihilation coincidence detection

Question 32 of 50

III. Pharmaceutical and Radiopharmaceutical Agents · NMTCB-032

During In-111 oxyquinoline leukocyte labeling, the technologist washes the white cells and resuspends them in saline before adding the In-111 oxine. Why does the label call for removing plasma first?

  • A. Plasma makes the cells clump, so removing it is needed only for patient comfort
  • B. Plasma raises the radiation dose to the technologist, so it is removed only as a safety step
  • C. Transferrin in plasma competes for In-111, so plasma lowers cell labeling efficiency
  • D. In-111 oxine labels only red cells unless plasma proteins are present to stop it
Show answer and explanation

Correct answer: C. The Indium In 111 Oxyquinoline label explains that the indium-oxyquinoline complex is neutral and lipid-soluble, which lets it penetrate the cell membrane; inside the cell, indium attaches firmly to cytoplasmic components. The label states that the presence of red cells or plasma reduces leukocyte labeling efficiency and that transferrin in plasma competes for indium In 111 oxyquinoline. That's why the white cell button is washed and resuspended in sodium chloride injection before the In-111 oxyquinoline is added. After labeling, the cells are resuspended in the patient's saved leukocyte-poor plasma for reinjection, and the label asks that labeled cells be used within one hour if possible and never more than three hours after preparation.

Why the other choices don't fit

  • A: The label does report cell clumping in some preparations, but the reason for removing plasma is transferrin competing for In-111, not clumping or comfort.
  • B: Removing plasma doesn't change the technologist's dose meaningfully. It is done to improve labeling efficiency.
  • D: In-111 oxine labels many cell types, including red cells. That is why leukocytes are separated first.

Source: DailyMed, Indium In 111 Oxyquinoline label (GE Healthcare), Clinical Pharmacology (neutral lipid-soluble complex; red cells or plasma reduce labeling; transferrin competes) and labeling procedure (saline wash and resuspension)

Question 33 of 50

V. Clinical Procedures · NMTCB-033

A patient is starting Pluvicto (lutetium Lu 177 vipivotide tetraxetan) treatment. What does the label give as the standard dosing schedule, and what should the patient be told about fluids?

  • A. 55 kBq/kg every 4 weeks for 6 doses; drink no more than usual after each injection
  • B. 7.4 GBq (200 mCi) every 6 weeks for 6 doses; increase oral fluids and void as often as possible
  • C. 7.4 GBq (200 mCi) once only; restrict fluids for 24 hours to keep the drug in the tumors
  • D. 3.7 GBq (100 mCi) every week for 6 weeks; avoid urinating for 6 hours after each dose
Show answer and explanation

Correct answer: B. The Pluvicto label recommends 7.4 GBq (200 mCi) every 6 weeks for 6 doses, or until disease progression or unacceptable toxicity. Patients are selected based on PSMA expression on a PSMA PET scan. For radiation safety, the label says to make sure patients increase oral fluid intake and to advise them to void as often as possible to reduce bladder radiation, and it repeats the hydration and frequent urination advice under renal toxicity.

Why the other choices don't fit

  • A: 55 kBq/kg every 4 weeks is the Xofigo (radium-223) regimen, not Pluvicto.
  • C: Pluvicto is a multi-dose course, and restricting fluids is the opposite of the label's advice.
  • D: The labeled dose and interval are 7.4 GBq every 6 weeks, and holding urine would increase bladder dose.

Source: DailyMed, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) label, Highlights and section 2.3 (7.4 GBq every 6 weeks for 6 doses); section 5.1 (radiation exposure: oral fluids, frequent voiding) and section 5.3 (renal toxicity)

Question 34 of 50

V. Clinical Procedures · NMTCB-034

Which patient matches the labeled indication for radium-223 dichloride (Xofigo)?

  • A. A man with castration-resistant prostate cancer whose only metastases are in the liver and lungs
  • B. A man with newly diagnosed hormone-sensitive prostate cancer and no metastases found on any imaging
  • C. A woman with breast cancer and painful bone metastases who also has several liver metastases
  • D. A man with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases
Show answer and explanation

Correct answer: D. The Xofigo label limits its indication to patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. The label's mechanism section explains that radium-223 mimics calcium and forms complexes with bone mineral (hydroxyapatite) at areas of increased bone turnover, such as bone metastases, which is why visceral disease falls outside the indication. The dose is 55 kBq (1.49 µCi) per kg every 4 weeks for 6 injections, given by slow intravenous injection over 1 minute, with the line flushed with saline before and after.

Why the other choices don't fit

  • A: The label excludes known visceral metastatic disease, and this patient has no bone metastases.
  • B: Hormone-sensitive disease without metastases isn't the labeled indication, which requires castration resistance and symptomatic bone metastases.
  • C: The indication is limited to prostate cancer, and visceral metastases are excluded.

Source: DailyMed, Xofigo (radium Ra 223 dichloride) label, section 1, Indications and Usage; section 2, Dosage and Administration (slow IV over 1 minute; saline flush before and after); section 12.1, Mechanism of Action

Question 35 of 50

IV. Instrument Operations and Quality Control · NMTCB-035

A gamma camera with paralysable dead time is imaging a very high activity. Why can the observed count rate be misleading at this level?

  • A. The count rate keeps climbing in a straight line, so counts at high activity overstate what is present
  • B. The count rate peaks and then falls as activity rises, so one observed rate can match two activities
  • C. The count rate drops to zero at once as soon as the dead time threshold is crossed by the camera
  • D. The count rate rises in steps, and each step changes the energy window setting for the camera
Show answer and explanation

Correct answer: B. The IAEA handbook describes two types of dead time. With non-paralysable dead time, the system is unresponsive for a fixed time after each event, so the observed count rate levels off and saturates at high activity. With paralysable dead time, an event arriving during the dead period also extends that period, so the observed rate peaks and then falls as activity increases further. That creates an ambiguity: the same observed count rate can correspond to two different activity levels. At moderate count rates, the two models behave alike. Real scanners behave somewhere between the two because some components are paralysable and others are not, which is why high-count-rate imaging (first-pass studies, high-activity therapy imaging) needs extra care.

Why the other choices don't fit

  • A: A straight-line response would mean no dead time losses. Dead time causes count losses at high activity, not overstatement.
  • C: The count rate doesn't drop to zero suddenly. A paralysable system declines gradually past its peak.
  • D: Dead time doesn't change energy window settings. It causes lost and mispositioned events.

Source: IAEA, Nuclear Medicine Physics: A Handbook for Teachers and Students (2014), Chapter 8, section 8.4.2, Dead time

Question 36 of 50

III. Pharmaceutical and Radiopharmaceutical Agents · NMTCB-036

A batch of autologous leukocytes has been labeled with Tc-99m exametazime (Ceretec). How soon should the labeled cells be reinjected, according to the label?

  • A. Any time within 24 hours, as long as the labeled cells are kept refrigerated
  • B. Within 6 hours, the same use window that applies to the cerebral perfusion preparation of the kit
  • C. Only after a 2-hour incubation, so the label can bind fully to the white cells
  • D. As soon as possible, preferably within 20 minutes and no later than 1 hour after labeling
Show answer and explanation

Correct answer: D. For the leukocyte labeling preparation, the Ceretec label directs reinjecting the labeled cells as soon as possible, preferably within 20 minutes, and not more than 1 hour after labeling. The adult leukocyte dose is 5 to 10 mCi of labeled cells, given through a 19-gauge needle. The label also says not to use the cobalt stabilizer solution for leukocyte labeling; the stabilizer belongs only to the cerebral perfusion preparation. Mixing up the two Ceretec preparations is the error to guard against, since each has its own steps and dose (15 to 30 mCi for cerebral scintigraphy).

Why the other choices don't fit

  • A: Refrigeration doesn't extend the use window for labeled autologous cells. The label limit is 1 hour.
  • B: The cerebral perfusion preparation follows separate directions. For labeled leukocytes, the label limit is 1 hour.
  • C: Labeling is done during the prep steps. Extra waiting after labeling hurts cell viability and isn't called for.

Source: DailyMed, Ceretec (technetium Tc99m exametazime) label, section 2.2, Leukocyte Labeled Scintigraphy (administer preferably within 20 minutes, no later than 1 hour; do not use cobalt stabilizer for leukocytes)

Question 37 of 50

V. Clinical Procedures · NMTCB-037

A patient scheduled for I-131 sodium iodide therapy mentions several issues during the pre-treatment interview. Which one is listed as a contraindication on the therapeutic sodium iodide I-131 label?

  • A. She had a negative pregnancy test this morning
  • B. She is breastfeeding her 4-month-old baby
  • C. She had a CT scan without contrast last year
  • D. She takes a daily multivitamin without iodine
Show answer and explanation

Correct answer: B. The therapeutic sodium iodide I-131 label lists these contraindications: vomiting and diarrhea, thyroid malignancies shown to have no iodide uptake, concurrent anti-thyroid therapy, pregnancy and lactation. A breastfeeding patient falls under lactation, so treatment shouldn't go ahead as planned, and the physician needs to know right away. The label's warnings separately cover increased radiation exposure to breast tissue with lactation. A negative pregnancy test is part of normal pre-therapy screening, not a contraindication.

Why the other choices don't fit

  • A: A negative pregnancy test is reassuring screening, not a contraindication. Pregnancy itself is the contraindication.
  • C: A non-contrast CT doesn't add an iodine load and isn't a labeled contraindication.
  • D: An iodine-free multivitamin isn't a contraindication on the label.

Source: DailyMed, Sodium Iodide I-131 label (Radnostix), section 4, Contraindications, and section 5.5, Increased Radiation Exposure to Breast Tissue with Lactation

Question 38 of 50

II. Radiation Safety and Regulations · NMTCB-038

A 200 µCi Cs-137 sealed reference source used for daily dose calibrator checks is leak tested. The wipe shows 0.007 µCi of removable contamination. What does 10 CFR 35.67 require?

  • A. Keep using the source and repeat the leak test in 6 months, the normal testing interval
  • B. Decontaminate the outside of the source with a damp wipe and return it to use the same day
  • C. Withdraw the source from use right away and file a report within 5 days of the leak test
  • D. Store it for decay in storage until it reads at background, then dispose of it as normal trash
Show answer and explanation

Correct answer: C. Under 10 CFR 35.67, sealed sources are leak tested before first use (unless the supplier certifies a test within the prior 6 months) and at intervals not to exceed 6 months. The test must be able to detect 185 Bq (0.005 µCi). If it shows 185 Bq (0.005 µCi) or more of removable contamination, the licensee must immediately withdraw the source from use, store, dispose of or repair it under Parts 20 and 30, and file a report within 5 days of the leak test. A result of 0.007 µCi is above that threshold. Some sources are exempt from leak testing, including those with a half-life under 30 days and those holding 100 µCi or less of beta or gamma emitters, but a 200 µCi Cs-137 source fits neither exemption.

Why the other choices don't fit

  • A: Routine 6-month testing applies to sources that pass. A result at or above 0.005 µCi triggers immediate withdrawal and a report.
  • B: Wiping the surface doesn't fix a leaking source, and the rule requires withdrawal and a report, not same-day return to use.
  • D: Decay-in-storage under 35.92 applies only to material with a half-life of 120 days or less. Cs-137's half-life is about 30 years, so this isn't an option.

Source: eCFR, 10 CFR 35.67, Requirements for possession of sealed sources, paragraphs (b), (c), (e) and (f); eCFR, 10 CFR 35.92, Decay-in-storage, paragraph (a)

Question 39 of 50

V. Clinical Procedures · NMTCB-039

A one-day rest/stress Myoview (Tc-99m tetrofosmin) myocardial perfusion study is planned. What dose pattern does the label describe?

  • A. A first dose of 15 to 33 mCi, then a second dose of 5 to 12 mCi about 24 hours later
  • B. Two equal doses of 33 mCi each, given 15 minutes apart, with imaging after the second
  • C. A first dose of 5 to 12 mCi, then a second dose of 15 to 33 mCi about 1 to 4 hours later
  • D. One dose of 5 mCi for both images, with stress imaging done right after the rest images
Show answer and explanation

Correct answer: C. The Myoview label recommends 185 to 1,221 MBq (5 to 33 mCi) for rest or stress imaging. When rest and stress injections are given on the same day, the first dose should be 185 to 444 MBq (5 to 12 mCi), followed by a second dose of 555 to 1,221 MBq (15 to 33 mCi) about 1 to 4 hours later. The larger second dose overwhelms the activity left in the myocardium from the first, so the second image reflects the second injection. The label also says imaging may begin 15 minutes after injection, and the material shouldn't be used if radiochemical purity is under 90%.

Why the other choices don't fit

  • A: The labeled pattern is low dose first, high dose second, on the same day.
  • B: Two maximal doses 15 minutes apart don't match the labeled same-day pattern and would add unnecessary radiation.
  • D: A single small dose can't produce separate rest and stress images.

Source: DailyMed, Myoview (tetrofosmin) label, Highlights and section 2.2, Recommended Dosage (same-day doses 5–12 mCi then 15–33 mCi 1 to 4 hours later); sections 2.5 and 2.6

Question 40 of 50

III. Pharmaceutical and Radiopharmaceutical Agents · NMTCB-040

A thyroid cancer patient is scheduled for Thyrogen-stimulated radioiodine imaging. Thyrogen 0.9 mg IM was given Monday at 08:00. According to the label, when should the second dose be given, and when should the radioiodine follow?

  • A. Second dose Tuesday at 08:00, then radioiodine Tuesday at 20:00
  • B. Second dose Tuesday at 08:00, then radioiodine Wednesday at 08:00
  • C. Second dose Monday at 20:00, then radioiodine Tuesday at 08:00
  • D. Second dose Wednesday at 08:00, then radioiodine Wednesday at 20:00
Show answer and explanation

Correct answer: B. The Thyrogen label gives 0.9 mg intramuscularly into the buttock as two injections 24 hours apart, followed by radioiodine 24 hours after the second injection. A first dose Monday at 08:00 means a second dose Tuesday at 08:00 and radioiodine Wednesday at 08:00. The label also schedules the diagnostic scan 48 hours after the radioiodine and the serum thyroglobulin sample 72 hours after the final Thyrogen injection.

Why the other choices don't fit

  • A: The second dose timing is right, but radioiodine is given 24 hours after the second dose, not 12.
  • C: The doses are 24 hours apart, not 12.
  • D: A 48-hour gap between doses and a 12-hour delay to radioiodine don't match the labeled schedule.

Source: DailyMed, Thyrogen (thyrotropin alfa) label, Dosage and Administration (0.9 mg IM every 24 hours for two doses; radioiodine 24 hours after the final injection)

Question 41 of 50

IV. Instrument Operations and Quality Control · NMTCB-041

A technologist needs to measure removable contamination on a set of wipe samples from a Tc-99m hot lab. Which instrument does the IAEA handbook describe as more accurate for counting wipes than a pancake probe?

  • A. A gamma camera with a pinhole collimator, which is required for all wipe tests
  • B. A cutie-pie ionization chamber, because low sensitivity is ideal for tiny samples
  • C. A dose calibrator, because it is designed for the lowest activities in the department
  • D. A NaI(Tl) well counter, which surrounds the sample in a nearly 4π counting geometry
Show answer and explanation

Correct answer: D. The IAEA handbook describes the well counter as a high-sensitivity device for counting specimens such as blood and urine samples and wipes from contamination surveys. A sample placed in the bore of a well-type NaI(Tl) crystal is almost completely surrounded by detector, approximating 4π geometry and a geometric efficiency near 100%. In its section on contamination monitoring, the handbook says the activity on a wipe can be assessed with a pancake probe, or more accurately in a well counter. Results are converted to activity with an isotope-specific calibration factor (cpm per MBq). The trade-off is that well counters are so sensitive they can reliably count only activities up to about 100 kBq; above that, dead time losses make counts inaccurate even with corrections.

Why the other choices don't fit

  • A: Wipe tests are counted in a well counter or with a probe. A gamma camera isn't required.
  • B: The cutie-pie's low sensitivity suits high radiation fields. It's a poor choice for tiny amounts of removable contamination.
  • C: A dose calibrator is designed for patient-dose activities (MBq to GBq). It isn't sensitive enough for low-level wipe counting.

Source: IAEA, Nuclear Medicine Physics: A Handbook for Teachers and Students (2014), Chapter 10, section 10.4.3, Well counter; Chapter 9, section 9.6.2, Wipe tests and daily surveys (wipe assessed more accurately in a well counter)

Question 42 of 50

V. Clinical Procedures · NMTCB-042

For in vivo red blood cell labeling with Technescan PYP, when is the stannous pyrophosphate given, and how much activity stays in the blood pool?

  • A. 15 to 30 minutes before the pertechnetate, with about 75% of the activity staying in the blood pool
  • B. At the same time as the pertechnetate, mixed in one syringe, with about 50% of the activity staying in the blood pool
  • C. Right after the pertechnetate, with about 25% of the activity staying in the blood pool
  • D. 24 hours before the pertechnetate, with nearly 100% of the activity staying in the blood pool
Show answer and explanation

Correct answer: A. The Technescan PYP label explains that when PYP reconstituted in 0.9% sodium chloride is given 15 to 30 minutes before intravenous sodium pertechnetate Tc 99m, about 75% of the administered activity remains in the blood pool, allowing imaging of the cardiac chambers. The stannous ion in the PYP 'tins' the red cells so pertechnetate that enters them is reduced and stays bound. The label's dosimetry assumes 75% of the pertechnetate labels red cells and 25% remains as free pertechnetate. The label adds that the modified in vivo/in vitro method gives comparable percentages.

Why the other choices don't fit

  • B: The label calls for the PYP 15 to 30 minutes before the pertechnetate, not in the same syringe.
  • C: Pertechnetate given before the stannous ion isn't trapped in red cells, and 25% is the share that stays as free pertechnetate in the label's dosimetry.
  • D: A 24-hour gap isn't the labeled timing, and in vivo labeling doesn't reach nearly 100%.

Source: DailyMed, Technescan PYP (technetium Tc 99m pyrophosphate) label, Clinical Pharmacology (PYP 15 to 30 minutes before pertechnetate; about 75% in blood pool) and Radiation Dosimetry table footnote

Question 43 of 50

I. Radiation Physics and Detection · NMTCB-043

A patient needs 3.0 mCi of Tl-201 at 09:00 tomorrow, exactly 24 hours from now. The Tl-201 label's decay chart lists a fraction remaining of 0.80 at 24 hours. How much Tl-201 should be drawn now so the dose is 3.0 mCi at injection time?

  • A. 3.60 mCi
  • B. 3.75 mCi
  • C. 2.40 mCi
  • D. 3.00 mCi
Show answer and explanation

Correct answer: B. This is a precalibration problem. Activity at injection equals activity now multiplied by the decay factor, so activity now equals the activity needed divided by the decay factor: 3.0 mCi ÷ 0.80 = 3.75 mCi. The Thallous Chloride Tl 201 label gives a physical half-life of 72.9 hours and a decay chart showing 0.80 remaining at 24 hours, so 3.75 mCi drawn now decays to 3.0 mCi by 09:00 tomorrow. Before injecting, the activity is still determined and recorded, since 10 CFR 35.63 requires that for each dosage before medical use. A quick check catches most errors here: a precalibrated dose must be larger than the target dose, never smaller.

Why the other choices don't fit

  • A: 3.60 mCi adds 20% instead of dividing by 0.80. It leaves the dose about 4% short at injection time (3.60 × 0.80 = 2.88 mCi).
  • C: 2.40 mCi comes from multiplying by 0.80 instead of dividing. That is the activity that would remain tomorrow if you drew 3.0 mCi today.
  • D: Drawing 3.0 mCi ignores 24 hours of decay, so the patient would receive about 2.4 mCi.

Source: DailyMed, Thallous Chloride Tl 201 label (Curium), section 11.2, Nuclear Physical Characteristics, and Table 4, Physical Decay Chart (half-life 72.9 h; 0.80 at 24 h); eCFR, 10 CFR 35.63, Determination of dosages of unsealed byproduct material for medical use, paragraph (a)

Question 44 of 50

III. Pharmaceutical and Radiopharmaceutical Agents · NMTCB-044

Radium-223 dichloride (Xofigo) is dosed at 55 kBq per kg of body weight. What is the dose for a 72 kg patient?

  • A. 39.6 MBq (about 1.07 mCi)
  • B. 0.76 MBq (about 21 µCi)
  • C. 5.50 MBq (about 149 µCi)
  • D. 3.96 MBq (about 107 µCi)
Show answer and explanation

Correct answer: D. Multiply the weight-based dose by body weight: 55 kBq/kg × 72 kg = 3,960 kBq = 3.96 MBq. Converting with 1 µCi = 37 kBq gives 3,960 ÷ 37 ≈ 107 µCi. The Xofigo label gives 55 kBq (1.49 µCi) per kg every 4 weeks for 6 injections, by slow intravenous injection over 1 minute, and has its own calculation that includes a decay correction factor from the reference date.

Why the other choices don't fit

  • A: 39.6 MBq is 10 times too high, a decimal error in converting kBq to MBq.
  • B: 0.76 comes from dividing 55 by 72 instead of multiplying. Weight-based doses are always the per-kg figure times body weight.
  • C: 5.50 MBq ignores the patient's weight and treats the per-kg figure as if it were a fixed 5.5 MBq dose.

Source: DailyMed, Xofigo (radium Ra 223 dichloride) label, Dosage and Administration (55 kBq [1.49 µCi] per kg; every 4 weeks for 6 injections; dose calculation)

Question 45 of 50

V. Clinical Procedures · NMTCB-045

A patient is having an I-123 sodium iodide thyroid uptake measurement with no imaging. What dose and earliest measurement time does the label describe?

  • A. About 100 µCi orally, with uptake measurement able to start at 6 hours
  • B. About 1 mCi orally, with uptake measurement allowed only after 48 hours
  • C. About 400 µCi orally, with uptake measurement able to start at 30 minutes
  • D. About 5 mCi IV, with uptake measurement required at exactly 2 hours
Show answer and explanation

Correct answer: A. The I-123 capsule label gives an oral dose of 3.7 to 14.8 MBq (100 to 400 µCi) for the average 70 kg patient. The lower end, 3.7 MBq (100 µCi), is recommended for uptake studies alone, and the higher end, 14.8 MBq (400 µCi), for thyroid imaging. Measurement of I-123 in the thyroid may start at 6 hours after the dose and should be done using standardized procedures.

Why the other choices don't fit

  • B: 1 mCi is above the labeled range, and the label allows measurement from 6 hours.
  • C: 400 µCi is the imaging dose, and the label sets 6 hours as the earliest uptake time.
  • D: I-123 for uptake is given orally in microcuries, not as a 5 mCi IV dose.

Source: DailyMed, Sodium Iodide I 123 capsules label (Curium), Dosage and Administration (100 µCi for uptake; 400 µCi for imaging; measurement may begin at 6 hours)

Question 46 of 50

II. Radiation Safety and Regulations · NMTCB-046

Which area does 10 CFR 35.70 specifically require a nuclear medicine department to survey with a radiation detection survey instrument at the end of each day of use?

  • A. Every room where a Tc-99m diagnostic dose was given, whether or not a written directive applied
  • B. A confinement room where a therapy patient who can't yet be released under 35.75 is staying
  • C. Only the waste storage room, since that is where most of the day's radioactive material collects
  • D. The area where an I-131 sodium iodide therapy capsule requiring a written directive was prepared
Show answer and explanation

Correct answer: D. 10 CFR 35.70 adds to the Part 20 survey requirements: at the end of each day of use, the licensee must survey all areas where unsealed byproduct material requiring a written directive was prepared for use or administered. Under 35.40, a written directive is required for I-131 sodium iodide above 30 µCi and for any therapeutic dosage of unsealed byproduct material, so an I-131 therapy prep area is covered. The rule specifically exempts areas where patients are confined because they can't be released under 35.75. Diagnostic Tc-99m doses don't need a written directive, so 35.70 itself doesn't name those rooms, though license commitments and Part 20 surveys still apply.

Why the other choices don't fit

  • A: 35.70 is tied to material that requires a written directive. Routine diagnostic Tc-99m doses don't require one.
  • B: 35.70(b) exempts areas where patients are confined because they can't be released under 35.75.
  • C: Waste storage areas fall under other survey and posting rules. 35.70 targets prep and administration areas for written-directive material.

Source: eCFR, 10 CFR 35.70, Surveys of ambient radiation exposure rate, paragraphs (a) and (b); eCFR, 10 CFR 35.40, Written directives, paragraph (a)

Question 47 of 50

V. Clinical Procedures · NMTCB-047

A gastric emptying study is acquired with simultaneous anterior and posterior images. At one time point, the stomach region of interest contains 36,000 counts anteriorly and 25,000 counts posteriorly. What is the geometric mean?

  • A. 11,000 counts
  • B. 30,000 counts
  • C. 30,500 counts
  • D. 61,000 counts
Show answer and explanation

Correct answer: B. The SNMMI gastric emptying guideline defines the geometric mean as the square root of the product of anterior and posterior counts in the region of interest. Here that is √(36,000 × 25,000) = √900,000,000 = 30,000 counts. The geometric mean corrects for the stomach contents moving between front and back (fundus to antrum) during emptying, which would otherwise change attenuation and the apparent count rate. The guideline prefers simultaneous acquisition on a dual-head camera, but sequential anterior and posterior images on a single-head camera are acceptable. The guideline's processing section also requires all data to be corrected for radioactive decay before percent gastric retention is reported.

Why the other choices don't fit

  • A: 11,000 is the difference between the views, which has no use in this calculation.
  • C: 30,500 is the arithmetic mean ((36,000 + 25,000) ÷ 2), not the geometric mean.
  • D: 61,000 is the sum of the two views, not the geometric mean.

Source: SNMMI, Procedure Guideline for Adult Solid-Meal Gastric-Emptying Study 3.0, Procedure, image acquisition (geometric mean = square root of anterior × posterior counts; dual-head preferred) and section G, Processing (decay correction)

Question 48 of 50

IV. Instrument Operations and Quality Control · NMTCB-048

Which phantom does the IAEA handbook describe for evaluating overall SPECT system performance at acceptance testing, quarterly, and after repair or preventive maintenance?

  • A. A four-quadrant bar phantom placed directly on the face of the uncollimated detector
  • B. A flood source used for the daily extrinsic uniformity check
  • C. A Jaszczak circular or elliptical phantom with inserts in an acrylic tank
  • D. A point source of Co-57 positioned at the center of the field of view
Show answer and explanation

Correct answer: C. The IAEA handbook describes Jaszczak circular and elliptical phantoms, along with the similar Carlson phantom, as tools for evaluating the overall performance of SPECT systems after a repair or preventive maintenance, during acceptance testing or in quarterly testing. They consist of an acrylic tank with inserts; all Jaszczak models have six solid spheres and six sets of cold rods, so one acquisition shows how well the reconstructed images resolve small cold structures. They can also be used to see how reconstruction filters affect resolution.

Why the other choices don't fit

  • A: Bar phantoms test planar spatial resolution and linearity. They don't evaluate reconstructed SPECT performance.
  • B: Flood sources test planar uniformity. They don't assess the reconstructed volume.
  • D: A point source is used for intrinsic uniformity and some resolution and center-of-rotation measurements, not overall SPECT image quality.

Source: IAEA, Nuclear Medicine Physics: A Handbook for Teachers and Students (2014), Chapter 15, section 15.2.2.6, Jaszczak circular and elliptical phantoms

Question 49 of 50

III. Pharmaceutical and Radiopharmaceutical Agents · NMTCB-049

Sincalide (Kinevac) is ordered for gallbladder stimulation during hepatobiliary imaging, and the department uses the label's alternative infusion to lower GI side effects. What dose and rate does the label give for this option?

  • A. 0.12 mcg/kg in 100 mL of saline infused over 50 minutes at 2 mL/min
  • B. 0.12 mcg/kg given as an IV push over 5 seconds, followed by a flush
  • C. 0.04 mcg/kg in 10 mL of saline infused over 3 minutes as one dose
  • D. 0.02 mcg/kg given as an IV push over 30 to 60 seconds, then repeated
Show answer and explanation

Correct answer: A. The Kinevac label lists, for gallbladder contraction, 0.02 mcg/kg intravenously over 30 to 60 seconds, with a second 0.04 mcg/kg dose if satisfactory contraction doesn't occur within 15 minutes. It also describes an alternative: 0.12 mcg/kg diluted in 100 mL of sodium chloride injection and infused at 2 mL per minute over 50 minutes to reduce gastrointestinal adverse reactions such as abdominal cramping and nausea. The label offers the slower infusion specifically to reduce those reactions. The same label lists a different infusion time (30 minutes) for the barium meal indication, so the indication matters when reading the dosing table.

Why the other choices don't fit

  • B: Pushing 0.12 mcg/kg in 5 seconds would be faster and likely more poorly tolerated than any labeled method.
  • C: 0.04 mcg/kg is the labeled second dose if contraction is poor after the first. It isn't the alternative infusion.
  • D: 0.02 mcg/kg over 30 to 60 seconds is the labeled bolus regimen, not the alternative infusion meant to reduce side effects.

Source: DailyMed, Kinevac (sincalide) label, Dosage and Administration, gallbladder contraction (0.02 mcg/kg over 30 to 60 seconds; 0.04 mcg/kg repeat; 0.12 mcg/kg in 100 mL over 50 minutes)

Question 50 of 50

V. Clinical Procedures · NMTCB-050

A jaundiced patient with a serum bilirubin of 9 mg/dL receives Tc-99m mebrofenin (Choletec). Compared with a patient with normal liver function, what does the label say about this patient?

  • A. A lower dose range (0.5 to 1 mCi) is suggested, since jaundice makes the liver take up the tracer much faster
  • B. The study can't be done, because the label lists bilirubin above 5 mg/dL as a contraindication
  • C. A higher dose range (3 to 10 mCi) is suggested, and more tracer may show up in the kidneys and bladder
  • D. Nothing changes, since bilirubin has no effect on how mebrofenin is handled by the body
Show answer and explanation

Correct answer: C. The Choletec label suggests 74 to 185 MBq (2 to 5 mCi) for a nonjaundiced patient and 111 to 370 MBq (3 to 10 mCi) for a patient with serum bilirubin above 1.5 mg/dL. It also notes that high serum bilirubin increases renal excretion of Tc-99m HIDA agents: in patients with a mean bilirubin of 9.8 mg/dL, about 3% of the injected dose was excreted in urine in the first 3 hours, compared with about 1% in normal subjects. On images, that can mean kidney and bladder activity, which shouldn't be confused with bowel or gallbladder. The label also advises fasting, with 4 hours preferable.

Why the other choices don't fit

  • A: The label raises the dose range for jaundiced patients. It doesn't lower it.
  • B: The only contraindication on the label is hypersensitivity to the compound. For high bilirubin, the label adjusts the dose instead.
  • D: The label specifically says high bilirubin increases renal excretion of HIDA agents.

Source: DailyMed, Choletec (technetium Tc 99m mebrofenin) label, Clinical Pharmacology (bilirubin increases renal excretion; 3% vs 1% urinary excretion in 3 hours) and Dosage and Administration

Score yourself by domain

Count your correct answers in each row. With 4 to 20 questions per domain, treat each result as a pointer to what to review, not a measure of readiness. NMTCB works the same way after a failed attempt: the score report ranks your relative performance by content area, while pass or fail depends on your overall result.

Score yourself by domain
NMTCB content domainOfficial share of the examQuestions on this pageYour score
I. Radiation Physics and Detection7%6, 18, 31, 43___ / 4
II. Radiation Safety and Regulations13%5, 13, 21, 30, 38, 46___ / 6
III. Pharmaceutical and Radiopharmaceutical Agents25%2, 7, 11, 15, 19, 24, 27, 32, 36, 40, 44, 49___ / 12
IV. Instrument Operations and Quality Control15%3, 10, 16, 23, 28, 35, 41, 48___ / 8
V. Clinical Procedures40%1, 4, 8, 9, 12, 14, 17, 20, 22, 25, 26, 29, 33, 34, 37, 39, 42, 45, 47, 50___ / 20
Total100%50___ / 50

The official percentages come from the NMTCB Components of Preparedness (COPS) content outline and NMTCB's exam page; the 2025 Annual Report says a 2023 job task analysis reconfirmed them. We scaled them to 50 questions and rounded: Clinical Procedures 20, Pharmaceutical and Radiopharmaceutical Agents 12, Instrument Operations and Quality Control 8, Radiation Safety and Regulations 6, Radiation Physics and Detection 4. A percentage on this page is your result on these 50 items only. It doesn't convert to an NMTCB scaled score.

If you want to practice at exam pace, the real exam gives 1 hour 55 minutes for 90 questions, about 77 seconds per question (115 ÷ 90 = 1.28 minutes). At that pace, these 50 questions take about 64 minutes. The real exam also doesn't let you skip a question or go back, so try answering each one before opening the explanation and don't return to change it.

What the real NMTCB exam looks like

What the real NMTCB exam looks like
DetailWhat NMTCB says
Credential and ownerCertified Nuclear Medicine Technologist (CNMT), awarded by the Nuclear Medicine Technology Certification Board (NMTCB). The CNMT program is accredited by the National Commission for Certifying Agencies (NCCA).
Questions90 questions, including unscored pretest questions mixed in. Every item is 4-option or 5-option multiple choice with one keyed answer.
Time1 hour 55 minutes, with a notice 15 minutes before time runs out
Test designComputer adaptive test for classification, offered since 1996. Items come in random content order. You can't skip a question or return to one, but you can change your answer before moving on.
ContentRadiation Physics and Detection 7%, Radiation Safety and Regulations 13%, Pharmaceutical and Radiopharmaceutical Agents 25%, Instrument Operations and Quality Control 15%, Clinical Procedures 40%
Where and when you testIQT Testing Centers, year-round. Apply at least 2 months before your desired test date; once approved, you have 3 months to test.
CalculatorBring your own. It must be noiseless, battery or solar powered, and unable to store text. Scratch paper is provided.
ScoringScaled from 200 to 500; 375 is the passing score. No penalty for guessing.
ResultsPreliminary results at the test site; the final score is mailed about three weeks later
EligibilityCompletion, within the previous five years, of an NMTCB-recognized or accredited nuclear medicine technology program (JRCNMT, Armed Forces Military Training Commands, CAMRT or ANZSNM oversight)
Keeping the credentialAnnual renewal and 24 continuing education hours every two years
Published pass rate89.69% for first-time program graduates in 2025; 82.22% across all 647 attempts

Sources: NMTCB, Program Graduate Application Instructions (fees, scheduling, eligibility, examination format, calculators, guessing, results, retakes, CE); NMTCB, Computer Adaptive Tests; NMTCB Annual Examination Report 2025, pages 5 to 9. As of November 18, 2026, NMTCB's exam page listed 21,556 active CNMT certificants. Fees and policies change, so confirm on NMTCB's site before you apply.

This page covers only the NMTCB exam. The ARRT also offers a nuclear medicine technology credential with its own exam; for that one, see our ARRT nuclear medicine practice test.

NMTCB exam fees

NMTCB exam fees
FeeAmount
Examination processing fee$200
Reactivation if you don't test within your 3-month window$100
One-time 3-month extension of the window (written request)$100
No-show at the testing center$200 (the full processing fee again)
Rescheduling through IQT, at least five business days ahead$25
Manual rescoring, requested within 2 months of the score report$50

Source: NMTCB, Program Graduate Application Instructions. The application fee is nonrefundable. If a candidate doesn't sit for the exam within one calendar year of eligibility approval, the full application fee is due again.

How the 375 passing score works

The NMTCB exam is a computer adaptive test built for classification. NMTCB says its goal is a pass or fail decision, so candidates are not rank-ordered along a score scale; the computer picks items that sort candidates accurately and quickly around the passing point. Because the test follows the content plan, it doesn't always serve a harder question after a correct answer. Once a minimum number of questions has been answered, testing stops when your performance is clearly above or below the passing standard with a set level of certainty, when the maximum number of questions is reached, or when time runs out.

Results are reported as a scaled score. Since January 1, 2018, the scale runs from 200 to 500, and the passing score is anchored at 375. NMTCB's annual report stresses that the scaled score is not a percentage, so 375 doesn't mean 75% correct. In 2025, the average scaled score across all attempts was 400.93.

What to review next, by domain

Use your domain scores to pick a starting point. These are the ideas the questions above lean on, with the sources that settle them.

What to review next, by domain
DomainReview these firstWhere the answers live
I. Radiation Physics and DetectionParent-daughter equilibrium, counting statistics and precision, annihilation radiation, decay and precalibration mathIAEA Nuclear Medicine Physics handbook, chapters 1 and 5; product decay tables on the DailyMed labels
II. Radiation Safety and RegulationsRadiation area postings, public and visitor dose limits, DOT label categories and transport index, survey meter calibration, sealed source leak tests, end-of-day surveyseCFR 10 CFR Part 20 and Part 35 sections; 49 CFR 172.403
III. Pharmaceutical and Radiopharmaceutical AgentsGenerator eluate limits, kit preparation steps (heat or no heat), MAA particle math, cell labeling chemistry, weight-based therapy doses, adjunct drugs like sincalide and thyrotropin alfaDailyMed labels for each product, especially Dosage and Administration and Clinical Pharmacology
IV. Instrument Operations and Quality ControlDose calibrator linearity and constancy, survey meter daily checks, energy resolution, Geiger versus ion chamber response, dead time, well counters, SPECT phantomsIAEA handbook, chapters 6, 8, 9, 10 and 15
V. Clinical ProceduresStress agent timing and contraindications, imaging windows for SPECT and PET agents, patient preparation, therapy indications and counseling, uptake doses, geometric mean, effects of disease on biodistributionDailyMed labels; SNMMI gastric emptying guideline

Clinical Procedures (40%) and Pharmaceutical and Radiopharmaceutical Agents (25%) together make up about two-thirds of the exam, so they move your result the most. The COPS outline describes tasks a new technologist does in the first year of practice, so practice explaining why a step comes in a given order or why a number is what it is, not only recalling the number.

NMTCB says it doesn't publish, produce or recommend any particular study guide, and points candidates to its content outlines and nationally recognized practice guidelines. NMTCB also posts a short set of sample exam questions that show the official item style; they are worth reading alongside this page.

Common questions about the NMTCB exam

How many questions are on the NMTCB exam?

90 questions in 1 hour 55 minutes, including unscored pretest questions you can't tell apart from the rest. Each one is 4-option or 5-option multiple choice (NMTCB application instructions).

What score do you need to pass the NMTCB?

375 on a scale of 200 to 500. The scale has been in use since January 1, 2018, and NMTCB notes that the scaled score is not a percentage (NMTCB Annual Report 2025, page 5).

What is the NMTCB pass rate?

In 2025, 89.69% of first-time program graduates passed (496 of 553). Across all 647 attempts the pass rate was 82.22%, and repeat examinees passed 36.67% of the time (33 of 90) (NMTCB Annual Report 2025, pages 6 to 9).

When can I take the NMTCB exam?

The exam is offered year-round at IQT Testing Centers. Your application and the $200 fee must arrive at least two months before the date you want, and once you're approved you have three months to test. Program directors can use NMTCB's early scheduling option so students can book before graduation, though the exam date itself must fall after graduation (NMTCB application instructions).

Are these real NMTCB exam questions?

No. We wrote every question on this page. They aren't official, recalled or adapted NMTCB items. NMTCB treats its examination as copyrighted, confidential material and doesn't recommend any particular study guide, so use these to practice applying the content outline, not to predict exam items (NMTCB, Certification Exams).

What happens if I fail the NMTCB exam?

After a first or second failure, you can apply to retake the exam two weeks after the date of that failure. After a third failure, you need 45 hours of approved coursework before testing again: currently 15 hours each in radiopharmacy, instrumentation and radiation safety, and from January 1, 2027, 5 hours in each of the five exam domains plus 20 general hours. That opens three more attempts. After six unsuccessful attempts, you must complete an approved nuclear medicine technology program to become eligible again. A failed attempt comes with a score report ranking your performance by content area, which helps you decide where to focus (NMTCB application instructions).

Sources

Exam facts:

Teaching content:

Last verified: November 19, 2026. We checked the exam format, fees, eligibility, scoring, pass rates and retake rules against NMTCB's application instructions, computer adaptive test page, COPS content outline and 2025 Annual Report, and each answer against the regulation, product label or reference cited with it. Product labels and regulations are revised from time to time, and your department's license conditions and procedures may be stricter, so check the current label and your local policy before acting on any detail.

By the Castleport Test Prep Editorial Team.

Castleport Test Prep is an independent exam prep publisher. We are not affiliated with, endorsed by, or approved by the Nuclear Medicine Technology Certification Board (NMTCB). NMTCB, CNMT, Certified Nuclear Medicine Technologist, product names and other exam and credential names are used only to identify their subjects; trademarks belong to their respective owners. These practice questions are original and unofficial.

No qualified nuclear medicine clinical or radiation safety review of this version is documented. This resource is for exam study, not clinical instructions.